Tonix Pharma ( (TNXP) ) just unveiled an update.
Tonix Pharmaceuticals has secured a new U.S. patent for its migraine treatment involving intranasal administration, with the patent expected to last until 2030. This breakthrough relates to their Tosymra® product and promises potential growth and a competitive edge in the market. While the announcement includes forward-looking statements about the company’s prospects and product development, investors are cautioned to consider the usual risks and uncertainties associated with such projections.
For detailed information about TNXP stock, go to TipRanks’ Stock Analysis page.
